圣达生物(603079) - 2022 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2022 was ¥185,166,102.76, representing a decrease of 3.52% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥20,799,549.32, down 11.07% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was ¥14,389,995.59, a decline of 25.22% compared to the previous year[5]. - The net profit for Q1 2022 was CNY 20,395,348.28, a decrease of 7.57% compared to CNY 22,063,598.84 in Q1 2021[22]. - The total profit for Q1 2022 was CNY 23,676,663.82, down from CNY 24,882,022.77 in the same period last year, reflecting a decline of 4.84%[22]. - Operating profit for Q1 2022 was CNY 23,531,335.07, compared to CNY 24,694,798.97 in Q1 2021, indicating a decrease of 4.69%[22]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥11,335,230.05, reflecting a significant decrease of 155.70%[5]. - Cash flow from operating activities showed a net outflow of CNY -11,335,230.05 in Q1 2022, contrasting with a net inflow of CNY 20,351,680.33 in Q1 2021[25]. - Cash and cash equivalents decreased to CNY 321,156,893.90 as of March 31, 2022, from CNY 514,747,873.78 at the end of 2021, a decline of 37.5%[16]. - Cash and cash equivalents at the end of Q1 2022 totaled CNY 296,238,667.03, down from CNY 391,247,468.23 at the end of Q1 2021[26]. - The total cash outflow from investing activities was CNY 218,711,963.09 in Q1 2022, compared to CNY 168,237,709.46 in Q1 2021, representing an increase of 30.06%[25]. Assets and Liabilities - The total assets at the end of the reporting period were ¥1,799,662,110.32, an increase of 1.97% from the end of the previous year[6]. - Total assets amounted to CNY 1,799,662,110.32, an increase from CNY 1,764,814,096.10 at the end of 2021, reflecting a growth of 2.0%[19]. - Total liabilities increased to CNY 442,295,269.44 from CNY 427,842,603.50, indicating a rise of 3.2%[18]. Shareholder Information - Basic and diluted earnings per share were both ¥0.12, down 14.29% from the same quarter last year[6]. - The company had a total of 17,100 common shareholders at the end of the reporting period[11]. - The company reported a basic and diluted earnings per share of CNY 0.12 for Q1 2022, down from CNY 0.14 in Q1 2021[22]. Operational Metrics - Total revenue for Q1 2022 was CNY 185,166,102.76, a decrease of 3.9% compared to CNY 191,930,642.69 in Q1 2021[20]. - Total operating costs for Q1 2022 were CNY 167,206,511.12, down from CNY 168,618,940.20 in Q1 2021, reflecting a slight reduction of 0.84%[20]. - Gross profit margin for Q1 2022 was approximately 9.5%, compared to 12.1% in Q1 2021, indicating a decline in profitability[20]. - Accounts receivable increased to CNY 155,019,748.61 from CNY 130,682,536.43, representing an increase of 18.6%[16]. - Inventory as of March 31, 2022, was CNY 266,760,488.09, up from CNY 222,087,972.31, marking an increase of 20.1%[17]. Future Outlook - The company plans to focus on expanding its market presence and investing in new product development in the upcoming quarters[20]. Expenses - The company experienced a 122.79% increase in selling expenses, attributed to higher bonus provisions during the period[10]. - The company incurred a credit impairment loss of CNY -1,568,940.87 in Q1 2022, compared to CNY -1,013,808.98 in Q1 2021, indicating a worsening of 55%[22].